Skip to main content

Northland Securities Sticks to Its Buy Rating for BioLife Solutions (BLFS)

Tipranks - Tipranks - Thu Jan 15, 12:48AM CST

Northland Securities analyst Carl Byrnes maintained a Buy rating on BioLife Solutions yesterday and set a price target of $34.00.

Claim 70% Off TipRanks Premium

Byrnes covers the Healthcare sector, focusing on stocks such as MiMedx Group, BioLife Solutions, and Indivior. According to TipRanks, Byrnes has an average return of -4.0% and a 36.34% success rate on recommended stocks.

In a report released yesterday, Lake Street also maintained a Buy rating on the stock with a $33.00 price target.

See the top stocks recommended by analysts >>

Based on BioLife Solutions’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $28.07 million and a net profit of $621 thousand. In comparison, last year the company earned a revenue of $30.57 million and had a GAAP net loss of $1.7 million

Based on the recent corporate insider activity of 111 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLFS in relation to earlier this year. Last month, Sarah Aebersold, the CHRO of BLFS sold 713.00 shares for a total of $17,439.98.

Read More on BLFS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).